drug · antibody
garetosmab
pre_registrationupdated 5mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
targets
Inhibin beta A chain
all catalysts(0)
nothing on the calendar yet
Trials studying garetosmab
- phase3A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- phase3A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
- —An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
- phase2A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
- phase1Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
News(3)
- Regeneron to challenge Ipsen as FDA clears bone disease drugPasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.biopharma_dive · 1mo ago
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 1mo ago
- FDA approves Regeneron’s garetosmab for disease that turns tissue to boneRegeneron has secured approval for its treatment for a debilitating disease that replaces muscle and connective tissue with bone. The FDA on Wednesday cleared the drugmaker’s activin A-targeting an…endpoints · 1mo ago
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that